GLP-1 Mental Health Side Effects: What the Research Actually Says About Depression and Anxiety

When a large cohort study published in Scientific Reports reported that patients on GLP-1 receptor agonists showed a 195% higher risk of major depression and a 106% elevated risk for suicidal behavior compared to non-users, it sent a ripple of concern through the medical community — and understandably so. But then, just two years later, a sweeping national cohort study from Sweden published in The Lancet Psychiatry found almost the opposite: semaglutide was associated with a 42% lower risk of worsening mental illness in people already diagnosed with depression or anxiety. Same drug class. Wildly different conclusions. If you’re on a GLP-1 medication — or considering one — and you’ve heard conflicting things about how these drugs affect your mental health, you’re not imagining the confusion. The science itself is genuinely conflicted, and understanding why matters far more than picking a side.

The Research Is Real — and Genuinely Complicated

To make sense of the contradictory headlines, you have to look at what each study was actually measuring and who it was studying. The 2024 Scientific Reports analysis by Kornelius and colleagues drew on post-marketing data from 2015 to 2023, using propensity score matching to compare over 162,000 patients on GLP-1 receptor agonists — specifically liraglutide and semaglutide — against matched controls who weren’t on these medications. Their findings were alarming on the surface: a 98% increased risk of any psychiatric disorder, a 195% increased risk of major depression, and a 106% elevated risk for suicidal behavior among GLP-1 users.

But here’s where study design becomes critical. People prescribed GLP-1 medications tend to have obesity, metabolic syndrome, type 2 diabetes, and a constellation of other health burdens that are themselves independent risk factors for depression and anxiety. Even with propensity score matching, it’s extraordinarily difficult to fully account for all the confounding variables — the years of health struggles, the psychological toll of chronic disease, the financial stress of medication access. The authors themselves acknowledged this limitation and called for urgent prospective clinical trials to clarify the picture.

The Swedish national cohort study from The Lancet Psychiatry, published in 2026 by Taipale and colleagues, took a fundamentally different methodological approach that helps address exactly that kind of confounding. Rather than comparing different people on versus off GLP-1 medications, researchers used a within-individual design — meaning they compared the same person’s mental health outcomes during periods when they were taking a GLP-1 agonist versus periods when they were not. This design is far more resistant to the kinds of baseline differences that plagued the earlier analysis. The cohort included nearly 95,500 individuals already diagnosed with depression, anxiety, or both, drawing from Sweden’s national electronic health registers across a 13-year span. The results were striking: semaglutide was associated with a 44% lower risk of worsening depression and a 38% lower risk of worsening anxiety, while GLP-1 receptor agonists as a group were associated with a 44% reduced risk of self-harm. Liraglutide showed more modest but still meaningful benefits, particularly for depression. Exenatide and dulaglutide showed no significant effect either way.

These aren’t small differences. And they suggest that for men who already carry a mental health diagnosis and are also dealing with obesity or diabetes, semaglutide in particular might be doing something genuinely therapeutic — not just metabolically, but neurologically.

What GLP-1 Medications Are Actually Doing in the Brain

The psychiatric effects of GLP-1 receptor agonists aren’t entirely surprising when you understand their mechanism of action beyond the gut. GLP-1 receptors are distributed throughout the central nervous system, including regions heavily implicated in mood regulation, reward processing, and stress response. A 2025 review by Himmerich and colleagues in Der Nervenarzt laid out the emerging neurological picture clearly: GLP-1 receptor agonists appear to have anti-inflammatory and neuroprotective effects in the brain, reducing oxidative stress, lowering the risk of ischemia, and potentially promoting neurogenesis. They also influence dopaminergic signaling in the nucleus accumbens — the brain’s primary reward hub — which is why researchers are increasingly interested in their potential for treating substance use disorders involving cocaine, alcohol, and nicotine.

Neuroinflammation is increasingly understood as a key driver of depression, particularly in men with metabolic dysfunction. Chronic low-grade inflammation — the kind that comes with visceral fat accumulation, insulin resistance, and poor sleep — is not confined to the body. It crosses into the brain and disrupts the neurotransmitter systems that regulate mood, motivation, and emotional resilience. If GLP-1 receptor agonists can genuinely dampen that inflammatory cascade and support neurogenesis, then their antidepressant and anxiolytic effects make biological sense. This isn’t speculation; it’s a plausible mechanism supported by the growing body of evidence the Himmerich review compiled, which also highlighted preliminary data suggesting therapeutic benefits for people with depression, anxiety, eating disorders, and substance use disorders.

A 2025 systematic review published in Brain and Behavior by Meshkat, Di Luciano, Swiderski and colleagues attempted to synthesize the clinical trial data on GLP-1 agonists and psychiatric outcomes across 26 studies involving over 3,000 participants. Their conclusion was measured but meaningful: liraglutide significantly improved depression and anhedonia in mood disorder patients, semaglutide improved both quality of life and anxiety compared to dulaglutide in people with type 2 diabetes, and exenatide produced mixed results across studies. Of nine randomized controlled trials included in the review, three showed statistically significant psychiatric benefits and six did not — which is why the authors called the overall evidence mixed and inconclusive, while acknowledging that the direction of effect leaned positive for mood-related outcomes.

The reality is that not all GLP-1 medications are created equal when it comes to psychiatric effects. Semaglutide consistently emerges as the most promising, possibly due to its longer half-life, its greater CNS penetration, or pharmacological differences that haven’t been fully characterized yet. Men who are lumping all GLP-1 agonists together when evaluating the mental health data are missing an important nuance.

What This Means If You’re Using a GLP-1 — or Managing Your Mental Health Without One

If you’re currently on semaglutide or liraglutide, the most current and methodologically rigorous evidence suggests you are not at elevated risk of developing depression or anxiety — and may, particularly if you already struggle with those conditions, be experiencing some psychiatric benefit alongside the metabolic ones. That’s not a reason to treat your GLP-1 medication as a psychiatric drug, but it is a reason to pay attention to your mental health in a genuinely curious rather than fearful way.

That said, the concern raised by the Kornelius study is not entirely dismissible. The population using GLP-1 medications skews toward people who have been metabolically and psychologically struggling for years. If you start semaglutide and find yourself feeling low, irritable, socially withdrawn, or unusually anxious — especially in the first several weeks — don’t automatically attribute it to the medication and don’t automatically dismiss it. Report it to your prescribing physician. The early period of significant appetite suppression and rapid weight loss can be physiologically and psychologically disruptive even when the drug itself isn’t causing harm directly. Rapid changes in body composition, shifts in social eating dynamics, and the nausea that often accompanies titration can all contribute to mood disruption that’s real but not necessarily drug-induced in the psychiatric sense.

There’s also an important consideration for men using antipsychotics or antidepressants who are dealing with medication-induced weight gain. A 2024 clinical review in Expert Opinion on Drug Safety by Solmi, Miola, Capone and colleagues specifically recommended considering GLP-1 receptor agonists as an adjunct to antipsychotic therapy to manage psychiatric medication-related weight gain — a population where the intersection of mental health and metabolic health is especially consequential. For these men, a GLP-1 medication might address two problems simultaneously.

For men who aren’t on GLP-1 medications and are managing their mental health through training, nutrition, and lifestyle — this research still has relevance. The same neuroinflammatory pathways that GLP-1 agonists appear to modulate can be meaningfully addressed through non-pharmacological means. Resistance training has well-documented antidepressant effects. Reducing visceral fat through a sustained calorie deficit lowers systemic inflammation. Improving insulin sensitivity through diet and exercise supports the same dopaminergic and serotonergic systems that GLP-1 drugs are influencing pharmacologically. You don’t need a prescription to move the needle on neuroinflammation and mood — but if you do have a prescription, the evidence suggests it’s probably not working against your mental health.

Regardless of your approach, mental health screening should be a non-negotiable part of any serious health optimization effort. Most men don’t talk about depression and anxiety, but both are profoundly common and profoundly intertwined with metabolic dysfunction. Low testosterone, poor sleep, chronic stress, and high body fat percentage aren’t just physical problems — they’re neurological ones. Addressing them directly, through whatever tools are appropriate for your situation, is the most complete definition of actually getting healthy.

The Takeaway

The relationship between GLP-1 receptor agonists and mental health is not a simple story of harm or benefit — it’s a nuanced picture that depends heavily on study design, population characteristics, and which specific medication is being examined. The most rigorous evidence currently available, particularly the Swedish national cohort study using within-individual comparisons, suggests that semaglutide in particular is associated with meaningful reductions in depression, anxiety, and self-harm risk in people who already carry those diagnoses. Liraglutide shows more modest but still real benefits. The alarming figures from the Kornelius analysis almost certainly reflect confounding by the underlying health burden of the GLP-1-using population rather than a direct causal psychiatric risk from the drugs themselves. What every man on a GLP-1 medication should do is stay self-aware, communicate openly with his doctor, and recognize that rapid metabolic change — however positive — can come with psychological adjustment. And what every man pursuing better health should understand is that your brain and your metabolic system are not separate projects. Fix one, and you’re likely helping the other.